Julia A. Haller

CIK: 0001656082

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)1 (12.5%)

Derivative conversions

Awards (A)7 (87.5%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

BMY

BRISTOL MYERS SQUIBB CO

Director

OTLK

Outlook Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (8 total)

BMY
BRISTOL MYERS SQUIBB CO
Jun 15, 2026
Exercise(M)
Direct
20.5K shares at avg. $53.76$1.1M
BMY
BRISTOL MYERS SQUIBB CO
Feb 1, 2026
Award(A)
Deferred Share Units
Direct
4K shares at avg. $55.05-
OTLK
Outlook Therapeutics, Inc.
Oct 3, 2025
Award(A)
Stock Option (Right to Buy)
Direct
58.6K shares-
OTLK
Outlook Therapeutics, Inc.
Oct 1, 2025
Award(A)
Stock Option (Right to Buy)
Direct
286.7K shares-
BMY
BRISTOL MYERS SQUIBB CO
Feb 1, 2025
Award(A)
Deferred Share Units
Direct
3.6K shares at avg. $58.95-
OTLK
Outlook Therapeutics, Inc.
Oct 3, 2024
Award(A)
Stock Option (Right to Buy)
Direct
12.1K shares-
OTLK
Outlook Therapeutics, Inc.
Oct 1, 2024
Award(A)
Stock Option (Right to Buy)
Direct
56.6K shares-
OTLK
Outlook Therapeutics, Inc.
Oct 1, 2024
Award(A)
Stock Option (Right to Buy)
Direct
47.2K shares-

		Type	Shares	Price		Ownership
Jun 15, 2026	BMY BRISTOL MYERS SQUIBB CO	Exercise(M)	20,460	$53.76	$1,099,930	Direct
Feb 1, 2026	BMY BRISTOL MYERS SQUIBB CO	Award(A) Deferred Share Units	3,996	$55.05	-	Direct
Oct 3, 2025	OTLK Outlook Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	58,648	-	-	Direct
Oct 1, 2025	OTLK Outlook Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	286,734	-	-	Direct
Feb 1, 2025	BMY BRISTOL MYERS SQUIBB CO	Award(A) Deferred Share Units	3,562	$58.95	-	Direct
Oct 3, 2024	OTLK Outlook Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	12,082	-	-	Direct
Oct 1, 2024	OTLK Outlook Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	56,636	-	-	Direct
Oct 1, 2024	OTLK Outlook Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	47,232	-	-	Direct

1-8 of 8 transactions

About Haller Julia A

Haller Julia A (SEC CIK 0001656082) files insider reports with the SEC as Director of BRISTOL MYERS SQUIBB CO (BMY) and Director of Outlook Therapeutics, Inc. (OTLK).

Signal8 holds 5 ownership filings by Haller Julia A, all Form 4s, filed between Oct 3, 2024 and Jun 16, 2026. Those filings report 8 transactions, from Oct 1, 2024 to Jun 15, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Haller Julia A's filings is in PRINCETON, NJ.

Recent filings by Haller Julia A

Jun 15, 2026: Option exercise of BMY shares (Form 4, code M).
Feb 1, 2026: Grant or award of BMY derivative securities (Form 4, code A).
Oct 3, 2025: Grant or award of OTLK derivative securities (Form 4, code A).
Oct 1, 2025: Grant or award of OTLK derivative securities (Form 4, code A).
Feb 1, 2025: Grant or award of BMY derivative securities (Form 4, code A).

Other insiders filing for BRISTOL MYERS SQUIBB CO (BMY)

BOERNER CHRISTOPHER S., Chief Executive Officer
Shanahan Karin, EVP, Chief Supply Chain & Ops
Meyers Gregory Scott, EVP, Chief Digital & Tech Off.
Gallman Cari, EVP, General Counsel
YALE PHYLLIS R, Director
Samuels Theodore R. II, Director

How to read Form 4 transaction codes